Cytochrome P450 3A4 Inducers

Cytochrome P450 2C9 Inducers

Isocitrate Dehydrogenase 1 Inhibitor

Isocitrate Dehydrogenase 1 Inhibitors

Leukemia, Myeloid, Acute

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11  DESCRIPTION</h1><p class="First">TIBSOVO (ivosidenib) is an inhibitor of isocitrate dehydrogenase 1 (IDH1) enzyme. The chemical name is (2<span class="Italics">S</span>)-<span class="Italics">N</span>-{(1<span class="Italics">S</span>)-1-(2-chlorophenyl)-2-[(3,3-difluorocyclobutyl)-amino]-2-oxoethyl}-1-(4-cyanopyridin-2-yl)-<span class="Italics">N</span>-(5-fluoropyridin-3-yl)-5-oxopyrrolidine-2-carboxamide. The chemical structure is:</p><div class="Figure"><img alt="Chemical Structure" src="tibsovo-01.jpg"/></div><p>The molecular formula is C<span class="Sub">28</span>H<span class="Sub">22</span>ClF<span class="Sub">3</span>N<span class="Sub">6</span>O<span class="Sub">3</span> and the molecular weight is 583.0 g/mol. Ivosidenib is practically insoluble in aqueous solutions between pH 1.2 and 7.4.</p><p>TIBSOVO (ivosidenib) is available as a film-coated 250 mg tablet for oral administration. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, croscarmellose sodium, hypromellose acetate succinate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. The tablet coating includes FD&amp;C blue #2, hypromellose, lactose monohydrate, titanium dioxide, and triacetin.</p></section>

TIBSOVO

ivosidenib

ivosidenib 250 MG Oral Tablet

Tibsovo

ivosidenib 250 MG Oral Tablet [Tibsovo]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information 

Medication Guide 

Submit MSL Request 

Pharmacy List

Coverage Authorization Request 

Coverage Authorization Appeals

Coding Guide

Other HCP Resources: Access 

Enroll in Patient Savings Program 

Servier One Enrollment Form 

Bridge Program - Max 2 Month Supply 

Comprehensive Support Program 

Other Patient Resources - Servier ONE for Cholangiocarcinoma (CCA)

Acute Myeloid Leukemia (AML) Factsheet 

Cholangiocarcinoma (CCA) Factsheet 

Patient Assistance Program 

About Tibsovo: Acute Myeloid Leukemia (AML)

Side Effects: Acute Myeloid Leukemia (AML)

Taking Tibsovo: Acute Myeloid Leukemia (AML)

Patient Resources: Acute Myeloid Leukemia (AML)

Patient Brochure: Acute Myeloid Leukemia (AML)

Instructions For Use: Acute Myeloid Leukemia (AML)

Other HCP Resources: Acute Myeloid Leukemia (AML)

Other HCP Resources: Cholangiocarcinoma (CCA)

About Tibsovo: Cholangiocarcinoma (CCA)

Side Effects: Cholangiocarcinoma (CCA)

Taking Tibsovo: Cholangiocarcinoma (CCA)

Patient Resources: Cholangiocarcinoma (CCA)

Patient Brochure: Cholangiocarcinoma (CCA)

Instructions For Use: Cholangiocarcinoma (CCA)

Sample Request